These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1236 related articles for article (PubMed ID: 8523067)

  • 1. Phase I studies of treatment of malignant gliomas and neoplastic meningitis with 131I-radiolabeled monoclonal antibodies anti-tenascin 81C6 and anti-chondroitin proteoglycan sulfate Me1-14 F (ab')2--a preliminary report.
    Bigner DD; Brown M; Coleman RE; Friedman AH; Friedman HS; McLendon RE; Bigner SH; Zhao XG; Wikstrand CJ; Pegram CN
    J Neurooncol; 1995; 24(1):109-22. PubMed ID: 8523067
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Iodine-131-labeled antitenascin monoclonal antibody 81C6 treatment of patients with recurrent malignant gliomas: phase I trial results.
    Bigner DD; Brown MT; Friedman AH; Coleman RE; Akabani G; Friedman HS; Thorstad WL; McLendon RE; Bigner SH; Zhao XG; Pegram CN; Wikstrand CJ; Herndon JE; Vick NA; Paleologos N; Cokgor I; Provenzale JM; Zalutsky MR
    J Clin Oncol; 1998 Jun; 16(6):2202-12. PubMed ID: 9626222
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment of intracranial human glioma xenografts with 131I-labeled anti-tenascin monoclonal antibody 81C6.
    Lee Y; Bullard DE; Humphrey PA; Colapinto EV; Friedman HS; Zalutsky MR; Coleman RE; Bigner DD
    Cancer Res; 1988 May; 48(10):2904-10. PubMed ID: 2452014
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dosimetry and radiographic analysis of 131I-labeled anti-tenascin 81C6 murine monoclonal antibody in newly diagnosed patients with malignant gliomas: a phase II study.
    Akabani G; Reardon DA; Coleman RE; Wong TZ; Metzler SD; Bowsher JE; Barboriak DP; Provenzale JM; Greer KL; DeLong D; Friedman HS; Friedman AH; Zhao XG; Pegram CN; McLendon RE; Bigner DD; Zalutsky MR
    J Nucl Med; 2005 Jun; 46(6):1042-51. PubMed ID: 15937318
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Intrathecal 131I-labeled antitenascin monoclonal antibody 81C6 treatment of patients with leptomeningeal neoplasms or primary brain tumor resection cavities with subarachnoid communication: phase I trial results.
    Brown MT; Coleman RE; Friedman AH; Friedman HS; McLendon RE; Reiman R; Felsberg GJ; Tien RD; Bigner SH; Zalutsky MR; Zhao XG; Wikstrand CJ; Pegram CN; Herndon JE; Vick NA; Paleologos N; Fredericks RK; Schold SC; Bigner DD
    Clin Cancer Res; 1996 Jun; 2(6):963-72. PubMed ID: 9816257
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Radioimmunotherapy of intracerebral human glioma xenografts with 131I-labeled F(ab')2 fragments of monoclonal antibody Mel-14.
    Colapinto EV; Zalutsky MR; Archer GE; Noska MA; Friedman HS; Carrel S; Bigner DD
    Cancer Res; 1990 Mar; 50(6):1822-7. PubMed ID: 2407345
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase I trial results of iodine-131-labeled antitenascin monoclonal antibody 81C6 treatment of patients with newly diagnosed malignant gliomas.
    Cokgor I; Akabani G; Kuan CT; Friedman HS; Friedman AH; Coleman RE; McLendon RE; Bigner SH; Zhao XG; Garcia-Turner AM; Pegram CN; Wikstrand CJ; Shafman TD; Herndon JE; Provenzale JM; Zalutsky MR; Bigner DD
    J Clin Oncol; 2000 Nov; 18(22):3862-72. PubMed ID: 11078500
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Therapeutic efficacy of antiglioma mesenchymal extracellular matrix 131I-radiolabeled murine monoclonal antibody in a human glioma xenograft model.
    Lee YS; Bullard DE; Zalutsky MR; Coleman RE; Wikstrand CJ; Friedman HS; Colapinto EV; Bigner DD
    Cancer Res; 1988 Feb; 48(3):559-66. PubMed ID: 2446747
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase II trial of murine (131)I-labeled antitenascin monoclonal antibody 81C6 administered into surgically created resection cavities of patients with newly diagnosed malignant gliomas.
    Reardon DA; Akabani G; Coleman RE; Friedman AH; Friedman HS; Herndon JE; Cokgor I; McLendon RE; Pegram CN; Provenzale JM; Quinn JA; Rich JN; Regalado LV; Sampson JH; Shafman TD; Wikstrand CJ; Wong TZ; Zhao XG; Zalutsky MR; Bigner DD
    J Clin Oncol; 2002 Mar; 20(5):1389-97. PubMed ID: 11870184
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dosimetry and dose-response relationships in newly diagnosed patients with malignant gliomas treated with iodine-131-labeled anti-tenascin monoclonal antibody 81C6 therapy.
    Akabani G; Cokgor I; Coleman RE; González Trotter D; Wong TZ; Friedman HS; Friedman AH; Garcia-Turner A; Herndon JE; DeLong D; McLendon RE; Zhao XG; Pegram CN; Provenzale JM; Bigner DD; Zalutsky MR
    Int J Radiat Oncol Biol Phys; 2000 Mar; 46(4):947-58. PubMed ID: 10705017
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Salvage radioimmunotherapy with murine iodine-131-labeled antitenascin monoclonal antibody 81C6 for patients with recurrent primary and metastatic malignant brain tumors: phase II study results.
    Reardon DA; Akabani G; Coleman RE; Friedman AH; Friedman HS; Herndon JE; McLendon RE; Pegram CN; Provenzale JM; Quinn JA; Rich JN; Vredenburgh JJ; Desjardins A; Gururangan S; Badruddoja M; Dowell JM; Wong TZ; Zhao XG; Zalutsky MR; Bigner DD
    J Clin Oncol; 2006 Jan; 24(1):115-22. PubMed ID: 16382120
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dosimetry of 131I-labeled 81C6 monoclonal antibody administered into surgically created resection cavities in patients with malignant brain tumors.
    Akabani G; Reist CJ; Cokgor I; Friedman AH; Friedman HS; Coleman RE; Zhao XG; Bigner DD; Zalutsky MR
    J Nucl Med; 1999 Apr; 40(4):631-8. PubMed ID: 10210222
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacokinetics and tumor localization of 131I-labeled anti-tenascin monoclonal antibody 81C6 in patients with gliomas and other intracranial malignancies.
    Zalutsky MR; Moseley RP; Coakham HB; Coleman RE; Bigner DD
    Cancer Res; 1989 May; 49(10):2807-13. PubMed ID: 2469537
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Improved therapeutic efficacy of a monoclonal antibody radioiodinated using N-succinimidyl-3-(tri-n-butylstannyl)benzoate.
    Schuster JM; Garg PK; Bigner DD; Zalutsky MR
    Cancer Res; 1991 Aug; 51(16):4164-9. PubMed ID: 1714341
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Human/murine chimeric 81C6 F(ab')(2) fragment: preclinical evaluation of a potential construct for the targeted radiotherapy of malignant glioma.
    Boskovitz A; Akabani GH; Pegram CN; Bigner DD; Zalutsky MR
    Nucl Med Biol; 2004 Apr; 31(3):345-55. PubMed ID: 15028247
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Monoclonal antibody and F(ab')2 fragment delivery to tumor in patients with glioma: comparison of intracarotid and intravenous administration.
    Zalutsky MR; Moseley RP; Benjamin JC; Colapinto EV; Fuller GN; Coakham HP; Bigner DD
    Cancer Res; 1990 Jul; 50(13):4105-10. PubMed ID: 2162252
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Distribution and dosimetry of I-123-labeled monoclonal antibody 81C6 in patients with anaplastic glioma.
    Schold SC; Zalutsky MR; Coleman RE; Glantz MJ; Friedman AH; Jaszczak RJ; Bigner SH; Bigner DD
    Invest Radiol; 1993 Jun; 28(6):488-96. PubMed ID: 7686539
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Human IgG2 constant region enhances in vivo stability of anti-tenascin antibody 81C6 compared with its murine parent.
    Reist CJ; Bigner DD; Zalutsky MR
    Clin Cancer Res; 1998 Oct; 4(10):2495-502. PubMed ID: 9796983
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparative localization of murine monoclonal antibody Me1-14 F(ab')2 fragment and whole IgG2a in human glioma xenografts.
    Colapinto EV; Humphrey PA; Zalutsky MR; Groothuis DR; Friedman HS; de Tribolet N; Carrel S; Bigner DD
    Cancer Res; 1988 Oct; 48(20):5701-7. PubMed ID: 3167830
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase-I/II radio-immunotherapy study with Iodine-131-labeled anti-CEA monoclonal antibody F6 F(ab')2 in patients with non-resectable liver metastases from colorectal cancer.
    Ychou M; Pelegrin A; Faurous P; Robert B; Saccavini JC; Guerreau D; Rossi JF; Fabbro M; Buchegger F; Mach JP; Artus JC
    Int J Cancer; 1998 Feb; 75(4):615-9. PubMed ID: 9466665
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 62.